Braillard, S.

Caljon, Guy

Hendrickx, Sarah

Leprohon, P.

Mabille, Dorien

Maes, Louis

Mowbray, C.E.

Ouellette, M.

Van den Kerkhof, Magali

Abstract: Current antileishmanial treatment is hampered by limitations such as drug toxicity and the risk of treatment failure, which may be related to parasitic drug resistance. Given the urgent need for novel drugs, the Drugs for Neglected Diseases initiative (DNDi) has undertaken a drug discovery program, which has resulted in the identification of aminopyrazoles - a highly promising antileishmanial chemical series. Multiple experiments have been performed to anticipate the propensity for resistance development

Institutional Repository Universiteit Antwerpen

Antileishmanial aminopyrazoles : studies into mechanisms and stability of experimental drug resistance

Antileishmanial aminopyrazoles : studies into mechanisms and stability of experimental drug resistance

Abstract

Similar works

Full text

Available Versions

Institutional Repository Universiteit Antwerpen